Jardiance and Heart Disease
A new study reports that Jardiance reduces the risk of acute cardiovascular episodes including heart attacks and strokes. Certified diabetes educator Sam Grossman looks at the study and provides analysis.
Posts
Statins: Risk Vs. Reward
Dr. Sam Grossman looks at statin use in people at risk for diabetes and discusses the risks versus the benefits.
7 Tips on Safety and Adherence to Medication on Vacation
Poor adherence to medical treatment is widespread and well recognized. Here are seven tips to help you adhere to your proper medication usage while on vacation.
No Increased Heart Risks for DPP-4 inhibitors
According to a study that was published in the New England Journal of Medicine, this class of drugs did not increase the risk for cardiovascular events, which was previously discussed and a concern in the medical community.
Who Can Benefit from the New U-200 Insulin?
Sam Grossman provides some information on the recently approved 200 unit/mL formulation of Eli Lilly and Company’s pre-filled pen containing insulin lispro (Humalog U-200 KwikPen).
Linking a Type 2 Drug to Too Much Acid in the Blood
The U.S. Food and Drug Administration (FDA) recently announced that sodium-glucose cotransporter-2 (SGLT2) inhibitors may be linked to cases of increased levels of acid in the blood. Sam Grossman talks about the FDA’s reporting on this subject.
Is a Cheaper, Off-Label Drug Better for Diabetic Eye Disease?
Genentech’s drug Avastin is used to treat cancer, but has also been used off-label for treatment of eye disease including diabetic retinopathy (DR). Sam Grossman discusses some of the studies’ findings of this medicine and whether people with DR may want to inquire with their healthcare providers about it.
GLP-1 Agonist Use in Type 1 Diabetes
Certified diabetes educator Amy Hess-Fischl talks about using GLP-1 agonists off-label in people with type 1 and shares some anecdotal evidence from patients as well as studies using this drug class in this patient population.
Preventing the Onset of Type 2 Diabetes
The Prevent Diabetes STAT: Screen, Test, Act–Today initiative and National Diabetes Prevention Program (NDPP) Lifestyle Change Programs are essential to stem the rising tide of diabetes.
New Heart Concerns for Existing Class of Type 2 Medications
An FDA Panel recommends new safety information on DPP-4 inhibitors Onglyza and Nesina. Sam Grossman reviews this news and how it may affect marketing and prescribing of the medications.
A New Long-Acting Insulin Option
Sanofi’s recently approved insulin, Toujeo, is 300u/ml and offers clinicians and people with diabetes who have glycemic control issues another long-acting insulin. Sam Grossman discusses some of the studies’ findings.
Meet the Swiss Army Knife of Diabetes Meters
The Dario glucose meter provides high functionality and numerous features to help make the life of people with diabetes easier. Andrew Stivelman reviews this high tech device and app and offers instructions into how to use them.
How to Choose the Right Eating Plan
Certified diabetes educator Amy Hess-Fischl offers some guidance in determining how to incorporate a healthier diet.
A New Treatment for Diabetic Retinopathy
The FDA recently approved Lucentis for use of diabetic retinopathy. Pharmacist and certified diabetes educator Sam Grossman talks about the clinical trial results for the new drug and considerations of how people with the complication may want to consider talking to their provider about it.
Overcoming Medication Adherence Challenges
Diabetes educator Debbie Berg discusses some strategies to make it easier to keep up with your regular regimen of medicine.